Evidence map›Paper›PMID 36749370›Full record

ArticleEuropean radiology2023

Time series radiomics for the prediction of prostate cancer progression in patients on active surveillance.

Nikita Sushentsev, Leonardo Rundo, Luis Abrego, Zonglun Li, Tatiana Nazarenko, Anne Y Warren, Vincent J Gnanapragasam, Evis Sala, Alexey Zaikin, Tristan Barrett and 1 more

Abstract read
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. [Cancer imaging : the official publication of the International Cancer Imaging Society · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Nikita SushentsevDepartment of Radiology, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK. ns784@medschl.cam.ac.uk.ORCID http://orcid.org/0000-0003-4500-9714
Leonardo RundoDepartment of Radiology, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Luis AbregoDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Zonglun LiDepartment of Mathematics, University College London, London, UK.
Tatiana NazarenkoDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Anne Y WarrenDepartment of Pathology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Vincent J GnanapragasamDepartment of Urology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Evis SalaDepartment of Radiology, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Alexey ZaikinDepartment of Women's Cancer, Institute for Women's Health, University College London, London, UK.
Tristan Barrett *Department of Radiology, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge Biomedical Campus, Box 218, Cambridge, CB2 0QQ, UK.
Oleg Blyuss *Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Serial MRI is an essential assessment tool in prostate cancer (PCa) patients enrolled on active surveillance (AS). However, it has only moderate sensitivity for predicting histopathological tumour progression at follow-up, which is in part due to the subjective nature of its clinical reporting and variation among centres and readers. In this study, we used a long short-term memory (LSTM) recurrent neural network (RNN) to develop a time series radiomics (TSR) predictive model that analysed longitudinal changes in tumour-derived radiomic features across 297 scans from 76 AS patients, 28 with histopathological PCa progression and 48 with stable disease. Using leave-one-out cross-validation (LOOCV), we found that an LSTM-based model combining TSR and serial PSA density (AUC 0.86 [95% CI: 0.78-0.94]) significantly outperformed a model combining conventional delta-radiomics and delta-PSA density (0.75 [0.64-0.87]; p = 0.048) and achieved comparable performance to expert-performed serial MRI analysis using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation (PRECISE) scoring system (0.84 [0.76-0.93]; p = 0.710). The proposed TSR framework, therefore, offers a feasible quantitative tool for standardising serial MRI assessment in PCa AS. It also presents a novel methodological approach to serial image analysis that can be used to support clinical decision-making in multiple scenarios, from continuous disease monitoring to treatment response evaluation. KEY POINTS: •LSTM RNN can be used to predict the outcome of PCa AS using time series changes in tumour-derived radiomic features and PSA density. •Using all available TSR features and serial PSA density yields a significantly better predictive performance compared to using just two time points within the delta-radiomics framework. •The concept of TSR can be applied to other clinical scenarios involving serial imaging, setting out a new field in AI-driven radiology research.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsHumansMagnetic Resonance ImagingMaleProstateRetrospective StudiesTime FactorsWatchful WaitingProstate-Specific AntigenArtificial intelligenceMagnetic resonance imagingProstatic neoplasms

Identifiers

PMID36749370
PMCPMC10182165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.